Latest news on Alzheimer's

The consortium has officially ended its formal operation after six years of joint efforts and collaboration.

As indicated by Biogen y Eisai, the results show a 27% slowing of cognitive impairment in patients in the early stages of Alzheimer's disease.

In the research, led by the Barcelonaβeta Brain Research Center (BBRC), a research center of the Pasqual Maragall Foundation, 314 people without cognitive alterations from the Alfa Study, which has the support of the ”la Caixa” Foundation, have participated - DESTACAT

Thanks to the Alfa study, which has the support of the ”la Caixa” Foundation, much progress has been made in recent years in the identification of the early pathophysiological characteristics of Alzheimer's disease, as well as in the its early detection and in the development of prevention strategies.

On World Alzheimer's Day, we want to make visible the need to continue allocating resources to erase this date from the calendar.

The Pasqual Maragall Researchers Program (PMRP) research grant program aims to promote clinical or translational research projects in Alzheimer's or other age-related neurodegenerative diseases.

More than 900 people without cognitive alterations from the Alfa Study, which has the support of the "la Caixa" Foundation, have participated in the research.

The study, which used data from almost 400 participants of the ALFA+ Study, determines that the biomarkers p-tau231 and p-tau217 measured in the blood are suitable for indicating brain changes related to the amyloid protein in people without cognitive symptoms.

Our research center will have a notable presence at the Alzheimer's Association International Conference (AAIC 2022), which will be held between July 31 and August 4 in San Diego.